The U.S. IPO market in mid-November 2026 is sending two messages at once. Deals are getting done, and deals are falling apart — sometimes the same deal, in the same week. For late-stage founders weighing a listing, the week's evidence is a useful corrective to the idea that an open window means an easy one.
The week's most closely watched pricing is vVardis Holding, a Swiss dental technology company that set terms on November 6 for a $214 million U.S. IPO. The company plans to offer 9.5 million shares at $21 to $24, implying a market value of about $1.3 billion at the midpoint of the range, and to list on the New York Stock Exchange under the symbol VVVV. Founded in 2020 in Zug, Switzerland, by sisters Dr. Haley Abivardi and Dr. Goly Abivardi, vVardis sells Curodont, a non-invasive treatment for early-stage cavities that works without drilling. It booked about $50 million in revenue for the twelve months ended June 30, 2026, against a net loss of $52.2 million, and distributes in the United States exclusively through Henry Schein. Apollo, the private equity firm, became a minority investor in April 2026. Goldman Sachs and J.P. Morgan lead the bookrunner group, and the deal is expected to price during the week of November 9. A second healthcare listing, biotech company Rezera, is also set to price this week, with the two deals together expected to raise about $414 million.
The Deal That Priced and Then Vanished
The counterpoint is OPay. The emerging-markets fintech priced its U.S. IPO at $19 per share — the low end of its $19 to $21 range — in late October, for an offering of about $304 million. Then, on October 30, it decided not to complete the offering. In a filing with the U.S. Securities and Exchange Commission on November 2, OPay said the decision followed a regulatory inquiry relating to a jurisdiction it described as immaterial to its business, and that it and the underwriters had mutually agreed to terminate the underwriting agreement signed on October 29. Its shares will not begin trading on the New York Stock Exchange as scheduled. The company said it expects the inquiry to be concluded satisfactorily and that the offering could be revived in the coming months.
OPay's prospectus showed why the deal mattered: lending, not payments, brought in 59.5% of its $467.1 million in first-half 2026 revenue. Nine investors had indicated non-binding interest in up to $270 million of the offering. None of that was enough once a regulatory question appeared. Pricing an IPO and completing one, the week demonstrated, are two different things.
SPACs Are Back, in Small Doses
Special purpose acquisition companies also returned to the week's news, in modest form. Two new SPAC filings appeared. ZA Acquisition I filed to raise $75 million by offering 7.5 million units at $10, targeting established businesses with recurring revenue, and plans to list on Nasdaq under the symbol ZACAU. It has a 12-month deadline to complete a combination, which is short for a SPAC. Research Alliance V, the fifth blank-check vehicle from RA Capital, filed for a $62 million IPO of 6.2 million shares at $10, targeting healthcare, life sciences and healthtech, and plans to list on Nasdaq under the symbol RACV. Unlike most SPACs, it does not plan to offer units with warrants or rights attached. RA Capital manages more than $15 billion in assets and has invested in 326 private companies, of which 156 have gone public or been acquired.
Not every filing survived the week either. Bitari, a bitcoin mining services provider, withdrew its planned $30 million IPO, with no specific reason cited in the available coverage.
What Late-Stage Founders Should Take From This
Three lessons stand out. First, the window is open for companies with a clear story and real revenue. A dental products company with $50 million in sales and a distinctive technology can price a $214 million offering. The market is not closed; it is selective.
Second, readiness must extend beyond the roadshow. OPay had a price, a ticker, underwriters and indicated demand — and still walked away on a regulatory question it called immaterial. Founders should treat regulatory, disclosure and governance diligence as part of the listing itself, not as paperwork that follows it. A surprise late in the process is far more expensive than the same issue found six months earlier.
Third, the SPAC route is returning, but in a different shape than the 2021 boom. The new filings are small, sponsor-led and sector-focused — a life-sciences specialist raising $62 million, a generalist targeting recurring-revenue businesses with $75 million — rather than the billion-dollar blank checks of the last cycle. For founders considering a SPAC merger, the sponsor's track record and the size of the trust matter far more than the headline.
The IPO market in November 2026 is neither hot nor frozen. It is a market that rewards preparation and punishes surprises. Founders who treat the listing as the finish line will be disappointed. Those who treat it as a diligence exercise that happens to end in a listing will be ready for either outcome.
Angeled.com connects founders with investors.
Renaissance Capital, "Emerging markets fintech OPay terminates its IPO after announcing pricing," November 2, 2026
OPay Form 6-K, U.S. Securities and Exchange Commission, November 2, 2026
Renaissance Capital, "SPAC ZA Acquisition I files for a $75 million IPO," November 9, 2026
Renaissance Capital, "RA Capital's SPAC Research Alliance V files for a $62 million IPO," November 9, 2026
IPOScoop, "The IPO Buzz: A Biotech & A Dental Care Start-Up On Tap," November 2026
Read Next
What a Reported $15B Raise at a $1.25T Valuation Would Mean for OpenAI — and Everyone Else
AlphaGenome 2 and the New Tooling Layer for Biotech Founders
Big Law Is Now Paying Lawyers to Learn AI — and That Changes Legal Tech
Biotech's $348 Million Week: Brain Drugs, Radiopharma and Gene Therapy
Databricks' Always-On Genie and the End of the Chatbot Era
Gemini Decision 1: Google's AI That Answers Instead of Chatting



